Hims & Hers Health Target of Unusually Large Options Trading (NYSE:HIMS)

Key Points

• Hims & Hers Health experienced unusually large options trading activity, with investors purchasing 302,107 call options, a 43% increase from the average daily volume.
• Insider selling has been significant, with CEO Andrew Dudum selling 65,110 shares and insiders overall selling 1,561,799 shares valued at approximately $80.69 million in the past 90 days.
• Despite a recent stock increase of 16.2%, Hims & Hers Health posted earnings that slightly missed analysts' estimates, reporting $0.17 EPS compared to expectations of $0.18 EPS.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors bought 302,107 call options on the stock. This represents an increase of 43% compared to the average daily volume of 211,116 call options.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $68.00 target price on shares of Hims & Hers Health in a research note on Friday, September 12th. Zacks Research downgraded shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Hims & Hers Health in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 65,110 shares of the firm's stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.57, for a total value of $3,292,612.70. Following the completion of the sale, the chief executive officer directly owned 95,315 shares in the company, valued at $4,820,079.55. This trade represents a 40.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Irene Becklund sold 8,410 shares of the firm's stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $424,705.00. Following the completion of the sale, the insider owned 1,418 shares of the company's stock, valued at $71,609. This trade represents a 85.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,561,799 shares of company stock valued at $80,686,085 over the last ninety days. 17.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in HIMS. Invesco Ltd. grew its position in Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock worth $127,237,000 after purchasing an additional 2,128,587 shares during the period. Nuveen LLC bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $58,403,000. Clear Street LLC bought a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $83,582,000. Norges Bank bought a new stake in Hims & Hers Health during the 2nd quarter worth approximately $78,464,000. Finally, Marex Group plc bought a new stake in Hims & Hers Health during the 2nd quarter worth approximately $53,626,000. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Up 16.2%

Shares of HIMS traded up $8.77 on Wednesday, hitting $62.79. 54,439,117 shares of the stock traded hands, compared to its average volume of 32,629,658. The company has a market capitalization of $14.19 billion, a PE ratio of 78.49, a P/E/G ratio of 3.74 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The business has a 50 day simple moving average of $50.66 and a 200 day simple moving average of $48.33. Hims & Hers Health has a one year low of $18.33 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same period last year, the firm posted $0.06 EPS. The company's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.